ScripSichuan Kelun Pharmaceutical has won an approval in China for its Merck & Co.-partnered sacituzumab tirumotecan (sac-TMT), a TROP2-targeting antibody-drug conjugate (ADC), which becomes the world’
Pink SheetThe novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regenxbio Calls On Nippon Shinyaku To
ScripAstellas is confident that it can ensure widespread testing for Claudin18.2 (CLDN18.2) among patients with gastric and gastroesophageal junction (G/GEJ) cancer as the first company to win approval for